Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb;38(2):287-289.
doi: 10.1161/ATVBAHA.117.310550.

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy

Xu Han  1 , Marvin T Nieman  2
Affiliations
Editorial

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy

Xu Han et al. Arterioscler Thromb Vasc Biol. 2018 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
The unique characteristics of PAR1 and PAR4 may provide an opportunity to fine tune thrombin signaling to optimize platelet response. A) PAR1 and PAR4 are distinct thrombin receptors that have different rates of activation and signaling kinetics. These receptors have complementary roles in hemostasis and cooperate to mediate thrombin signaling in platelets. B) Hemostasis (top left) starts from initial platelet adhesion and activation to form an unstable thrombus. Following additional thrombin generation and fibrin deposition, a stable thrombus forms to stop the bleeding. Thrombosis (top right) is the uncontrolled growth of the thrombus that obstructs blood flow. Inhibition of PAR1 (bottom left) with vorapaxar targets the initial stages of platelet activation at low thrombin concentrations. Inhibition of PAR4 (bottom right) with BMS-986120 targets the later stages of thrombus growth, which preserves the initial platelet aggregation mediated by PAR1.
See this image and copyright information in PMC

Comment on

References

    1. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879–87. - PMC - PubMed
    1. Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem. 2000;275:40671–8. - PubMed
    1. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J. 2003;376:733–40. - PMC - PubMed
    1. Nieman MT, Schmaier AH. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry. 2007;46:8603–10. - PMC - PubMed
    1. Sidhu TS, French SL, Hamilton JR. Differential signaling by protease-activated receptors: implications for therapeutic targeting. Int J Mol Sci. 2014;15:6169–83. - PMC - PubMed

Substances